Stem Cell Oncology–Pipeline Insights, 2016

NEW DELHI - March 6, 2016 - PRLog -- The Indication pipeline Insight Reports provides client with details onStem Cell OncologyPipeline products across the globe. It comprehensively includes:

·         Comparative study of drugs under development.

·         Information on several other drugs as well among which 2 are in phase III, 2 in phase II, 4 in phase I, 5 in pre - clinical and 5 are in dormant phase.

·         R&D activities and technologies used along with the pipeline molecules in development.

·         Information related to collaborations, in-licensing and out-licensing deals.

·         Stages of development of pipeline molecules.

·         Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

Report Coverage:
·         20+ Products, 10+ Companies

Stem Cell Oncology- Pipeline Insights, 2016 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore, DelveInsight’s report on Stem Cell Oncologyhelps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.

DelveInsight is offering the Report at a price of US 1,450 as a single user license, USD 2,900 as a site license and USD 4,500 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm.  DelveInsight help the clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.